PCM
HBIO icon

Portolan Capital Management’s Harvard Bioscience HBIO Stock Holding History

Portolan Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,965
Closed -$274K – 153
2025
Q4 		$274K Buy
+40,965
New +$243K 0.01% 155
2024
Q3 		– Sell
-1,200
Closed -$34.2K – 140
2024
Q2 		$34.2K Sell
1,200
-68,584
-98% -$2.41M ﹤0.01% 117
2024
Q1 		$2.96M Buy
69,784
+2,567
+4% +$115K 0.23% 103
2023
Q4 		$3.6M Buy
67,217
+22,127
+49% +$999K 0.31% 90
2023
Q3 		$1.94M Sell
45,090
-33,269
-42% -$1.54M 0.18% 109
2023
Q2 		$4.3M Sell
78,359
-25,996
-25% -$1.43M 0.38% 76
2023
Q1 		$4.38M Sell
104,355
-1,075
-1% -$31.9K 0.42% 78
2022
Q4 		$2.92M Sell
105,430
-28,779
-21% -$709K 0.29% 96
2022
Q3 		$3.44M Sell
134,209
-110,977
-45% -$3.67M 0.36% 95
2022
Q2 		$8.83M Sell
245,186
-7,493
-3% -$338K 0.89% 45
2022
Q1 		$15.7M Sell
252,679
-1,201
-0.5% -$71K 1.25% 22
2021
Q4 		$17.9M Buy
253,880
+18,079
+8% +$1.29M 1.2% 30
2021
Q3 		$16.5M Buy
235,801
+54,013
+30% +$4.3M 1.2% 34
2021
Q2 		$15.1M Buy
181,788
+20,707
+13% +$1.46M 1.09% 36
2021
Q1 		$8.79M Buy
161,081
+27,163
+20% +$1.32M 0.69% 60
2020
Q4 		$5.75M Buy
133,918
+36,011
+37% +$1.34M 0.52% 73
2020
Q3 		$2.95M Buy
97,907
+39,978
+69% +$1.34M 0.33% 97
2020
Q2 		$1.8M Buy
+57,929
New +$1.56M 0.21% 113

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Portolan Capital Management's HBIO Position: Q1 2026 in Review

Portolan Capital Management sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 40,965 shares — an estimated $274K sold.

Portolan Capital Management first reported a position in HBIO in Q2 2020 and held it in 18 quarters. The position peaked at $17.9M in Q4 2021. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Portolan Capital Management reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Portolan Capital Management sold 40,965 Harvard Bioscience shares in Q1 2026, an estimated $274K.
  • Portolan Capital Management first reported a position in Harvard Bioscience in Q2 2020 and held it in 18 quarters.
  • Portolan Capital Management's Harvard Bioscience position peaked at $17.9M in Q4 2021.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Portolan Capital Management's 13F filing for Q1 2026, filed 15 May 2026.